Sfoglia per Autore
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: attempts to improve long-term outcome
file da validare1995-01-01 Santoro, A; Soto Parra, H.; Bidoli, P; Angelidou, M; Cataldo, I; Salvini, P; Valagussa, P; Milani, F; Ravasi, G; Bonadonna, G
Ifosfamide and vinorelbine: An active regimen for patients with relapsed or refractory Hodgkin's disease
1998-01-01 Bonfante, V.; Viviani, S.; Santoro, A.; Devizzi, L.; Di Russo, A.; Zanini, M.; Soncini, F.; Soto Parra, H.; Valagussa, P.; Bonadonna, G.
Nutritional support in patients with cancer of the esophagus: Impact on nutritional status, patient compliance to therapy, and survival
file da validare1998-01-01 Bozzetti, F.; Cozzaglio, L.; Gavazzi, C.; Bidoli, P.; Bonfanti, G.; Montalto, F.; Soto Parra, H; Valente, Marcella; Zucali, R.
Soft tissue and bone sarcomas
file da validare1999-01-01 Santoro, Armando; Soto Parra, H
Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study
file da validare2000-01-01 Santoro, A.; Bredenfeld, H.; Devizzi, L.; Tesch, H.; Bonfante, V.; Viviani, S.; Fiedler, F.; Soto Parra, H.; Benoehr, C.; Pacini, M.; Bonadonna, G.; Diehl, V.
The evolution of surgery in non-small cell lung cancer
file da validare2000-01-01 Alloisio, M.; Infante, M.; Cariboni, U.; Testori, A.; Soto Parra, H.; Ravasi, G.
Treatment perspectives in advanced non-small cell lung cancer
file da validare2000-01-01 SOTO PARRA, Hector; Latteri, F.; Cavina, R.; Sala, A.; Dambrosio, M.; Alloisio, M.; Santoro, A.
Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus
file da validare2001-01-01 Bidoli, P; Stani, S C; De Candis, D; Cortinovis, D; Soto Parra, H.; Bajetta, E
Combined regimen of cisplatin, doxorubicin, and α-2b interferon in the treatment of advanced malignant pleural mesothelioma: A phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)
2001-01-01 Soto Parra, H.; Tixi, L.; Latteri, F.; Bretti, S.; Alloisio, M.; Gravina, A.; Lionetto, R.; Bruzzi, P.; Dani, C.; Rosso, R.; Cosso, M.; Balzarini, L.; Santoro, A.; Ardizzoni, A.
Three-week versus four-week schedule of cisplatin and gemcitabine: Results of a randomized phase II study
2002-01-01 Santoro, A.; Soto Parra, H.; Cavina, R.; Latteri, F.; Sala, A.; Dambrosio, M.; Antonelli, G.; Morenghi, E.; Alloisio, M.; Ravasi, G.
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: Clinical and molecular results from a prospective study
file da validare2002-01-01 Bertuzzi, A.; Castagna, L.; Nozza, A.; Quagliuolo, V.; Siracusano, L.; Balzarotti, M.; Compasso, S.; Alloisio, M.; Soto Parra, H.; Santoro, A.
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
2003-01-01 Cappuzzo, Federico; Ardizzoni, Andrea; Soto-Parra, Hector; Gridelli, Cesare; Maione, Paolo; Tiseo, Marcello; Calandri, Cesare; Bartolini, Stefania; Santoro, Armando; Crinò, Lucio
Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour
2003-01-01 Bertuzzi, A.; Castagna, L.; Quagliuolo, V.; Ginanni, V.; Compasso, S.; Magagnoli, M.; Balzarotti, M.; Nozza, A.; Siracusano, L.; Timofeeva, I.; Sarina, B.; Soto Parra, H.; Santoro, A.
Extensive experience of disease control with gefitinib and the role of prognostic markers
2003-01-01 Cortes-Funes, H.; Soto Parra, H.
Lessons from the ‘iressa’ expanded access programme: Gefitinib in special non-small-cell lung cancer patient populations
2003-01-01 Stahel, R.; Rossi, A.; Petruzelka, L.; Kosimidis, P.; Braud, F. D.; Bernardo, M. M.; Souquet, P. -J.; Soto Parra, H.; Gridelli, C.
Uncommon manifestations of common malignancies - Case 1. Soft-tissue metastases from malignant pleural mesothelioma
2004-01-01 Soto Parra, H.; Zucali, P. A.; Colombo, P.; Balzarini, L.; Santoro, A.
Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-smal-cell lung cancer
2004-01-01 Santoro, A.; Cavina, R.; Latteri, F.; Zucali, P. A.; Ginanni, V.; Campagnoli, E.; Ferrari, B.; Morenghi, E.; Pedicini, V.; Roncalli, M.; Alloisio, M.; Ravasi, G.; Soto Parra, H.
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
2004-01-01 Soto Parra, H.; Cavina, R.; Latteri, F.; Zucali, P. A.; Campagnoli, E.; Morenghi, E.; Grimaldi, G. C.; Roncalli, M.; Santoro, A.
Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: A new category of patients for clinical studies?
2005-01-01 Soto Parra, H.; Latteri, F.; Cavina, R.; De Vincenzo, F.; Zucali, P. A.; Campagnoli, E.; Santoro, A.
Lack of response to imatinib mesylate as second-line therapy in a patient with c-kit positive metastatic soft tissue leiomyosarcoma
file da validare2005-01-01 Silvestris, Nicola; Soto Parra, Hector; Angelini, Francesco; Di Cosimo, Serena; D'Aprile, Modesto; Santoro, Armando
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: attempts to improve long-term outcome | 1-gen-1995 | Santoro, A; Soto Parra, H.; Bidoli, P; Angelidou, M; Cataldo, I; Salvini, P; Valagussa, P; Milani, F; Ravasi, G; Bonadonna, G | file da validare |
Ifosfamide and vinorelbine: An active regimen for patients with relapsed or refractory Hodgkin's disease | 1-gen-1998 | Bonfante, V.; Viviani, S.; Santoro, A.; Devizzi, L.; Di Russo, A.; Zanini, M.; Soncini, F.; Soto Parra, H.; Valagussa, P.; Bonadonna, G. | |
Nutritional support in patients with cancer of the esophagus: Impact on nutritional status, patient compliance to therapy, and survival | 1-gen-1998 | Bozzetti, F.; Cozzaglio, L.; Gavazzi, C.; Bidoli, P.; Bonfanti, G.; Montalto, F.; Soto Parra, H; Valente, Marcella; Zucali, R. | file da validare |
Soft tissue and bone sarcomas | 1-gen-1999 | Santoro, Armando; Soto Parra, H | file da validare |
Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study | 1-gen-2000 | Santoro, A.; Bredenfeld, H.; Devizzi, L.; Tesch, H.; Bonfante, V.; Viviani, S.; Fiedler, F.; Soto Parra, H.; Benoehr, C.; Pacini, M.; Bonadonna, G.; Diehl, V. | file da validare |
The evolution of surgery in non-small cell lung cancer | 1-gen-2000 | Alloisio, M.; Infante, M.; Cariboni, U.; Testori, A.; Soto Parra, H.; Ravasi, G. | file da validare |
Treatment perspectives in advanced non-small cell lung cancer | 1-gen-2000 | SOTO PARRA, Hector; Latteri, F.; Cavina, R.; Sala, A.; Dambrosio, M.; Alloisio, M.; Santoro, A. | file da validare |
Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus | 1-gen-2001 | Bidoli, P; Stani, S C; De Candis, D; Cortinovis, D; Soto Parra, H.; Bajetta, E | file da validare |
Combined regimen of cisplatin, doxorubicin, and α-2b interferon in the treatment of advanced malignant pleural mesothelioma: A phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP) | 1-gen-2001 | Soto Parra, H.; Tixi, L.; Latteri, F.; Bretti, S.; Alloisio, M.; Gravina, A.; Lionetto, R.; Bruzzi, P.; Dani, C.; Rosso, R.; Cosso, M.; Balzarini, L.; Santoro, A.; Ardizzoni, A. | |
Three-week versus four-week schedule of cisplatin and gemcitabine: Results of a randomized phase II study | 1-gen-2002 | Santoro, A.; Soto Parra, H.; Cavina, R.; Latteri, F.; Sala, A.; Dambrosio, M.; Antonelli, G.; Morenghi, E.; Alloisio, M.; Ravasi, G. | |
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: Clinical and molecular results from a prospective study | 1-gen-2002 | Bertuzzi, A.; Castagna, L.; Nozza, A.; Quagliuolo, V.; Siracusano, L.; Balzarotti, M.; Compasso, S.; Alloisio, M.; Soto Parra, H.; Santoro, A. | file da validare |
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC) | 1-gen-2003 | Cappuzzo, Federico; Ardizzoni, Andrea; Soto-Parra, Hector; Gridelli, Cesare; Maione, Paolo; Tiseo, Marcello; Calandri, Cesare; Bartolini, Stefania; Santoro, Armando; Crinò, Lucio | |
Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour | 1-gen-2003 | Bertuzzi, A.; Castagna, L.; Quagliuolo, V.; Ginanni, V.; Compasso, S.; Magagnoli, M.; Balzarotti, M.; Nozza, A.; Siracusano, L.; Timofeeva, I.; Sarina, B.; Soto Parra, H.; Santoro, A. | |
Extensive experience of disease control with gefitinib and the role of prognostic markers | 1-gen-2003 | Cortes-Funes, H.; Soto Parra, H. | |
Lessons from the ‘iressa’ expanded access programme: Gefitinib in special non-small-cell lung cancer patient populations | 1-gen-2003 | Stahel, R.; Rossi, A.; Petruzelka, L.; Kosimidis, P.; Braud, F. D.; Bernardo, M. M.; Souquet, P. -J.; Soto Parra, H.; Gridelli, C. | |
Uncommon manifestations of common malignancies - Case 1. Soft-tissue metastases from malignant pleural mesothelioma | 1-gen-2004 | Soto Parra, H.; Zucali, P. A.; Colombo, P.; Balzarini, L.; Santoro, A. | |
Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-smal-cell lung cancer | 1-gen-2004 | Santoro, A.; Cavina, R.; Latteri, F.; Zucali, P. A.; Ginanni, V.; Campagnoli, E.; Ferrari, B.; Morenghi, E.; Pedicini, V.; Roncalli, M.; Alloisio, M.; Ravasi, G.; Soto Parra, H. | |
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer | 1-gen-2004 | Soto Parra, H.; Cavina, R.; Latteri, F.; Zucali, P. A.; Campagnoli, E.; Morenghi, E.; Grimaldi, G. C.; Roncalli, M.; Santoro, A. | |
Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: A new category of patients for clinical studies? | 1-gen-2005 | Soto Parra, H.; Latteri, F.; Cavina, R.; De Vincenzo, F.; Zucali, P. A.; Campagnoli, E.; Santoro, A. | |
Lack of response to imatinib mesylate as second-line therapy in a patient with c-kit positive metastatic soft tissue leiomyosarcoma | 1-gen-2005 | Silvestris, Nicola; Soto Parra, Hector; Angelini, Francesco; Di Cosimo, Serena; D'Aprile, Modesto; Santoro, Armando | file da validare |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile